Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 7/20 | 0.38 |
| ▸ | TACR2 | P21452 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | OXTR | P30559 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.32 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 2/20 | 0.32 |
| ▸ | CCND1 | P24385 | 2/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2407217 | 0.93 | TACR2 (0.37) | TACR2OXTRAVPR1ABCHECDK4 | |
| SCHEMBL2406776 | 0.89 | HTR6 (0.43) | TACR2OXTRAVPR1AHTR1ABCHE | |
| SCHEMBL2410775 | 0.89 | MPO (0.41) | MPOTACR2SLC6A4GPR84HTR1A | |
| SCHEMBL2403466 | 0.88 | HTR2A (0.41) | TACR2GPR84OXTRAVPR1ALPAR1 | |
| SCHEMBL1974495 | 0.87 | HTR6 (0.41) | TACR2SLC6A4OXTRAVPR1AHTR1A | |
| SCHEMBL1967482 | 0.87 | TACR2 (0.48) | TACR2BCHECDK4CCND1 | |
| SCHEMBL2410555 | 0.85 | MPO (0.38) | MPOSLC6A4 | |
| SCHEMBL1971560 | 0.85 | TACR2 (0.46) | TACR2CDK4CCND1 | |
| SCHEMBL2403399 | 0.85 | HTR1A (0.41) | TACR2SLC6A4OXTRAVPR1AHTR1A | |
| SCHEMBL2406957 | 0.85 | HTR1A (0.43) | MPOSLC6A4HTR1ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | MPO 3915/4885TACR2 90/4885SLC6A4 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.